285130.KS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 02:30):

Stats
Today's Volume	12 285.00
Average Volume	35 816.00
Market Cap	1 052.95B
EPS	KRW0 ( 2024-02-13 )
Next earnings date	( KRW0 ) 2024-05-12
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW79.08 (0.14%)

Volume Correlation

Long: -0.07 (neutral)

Short: -0.27 (neutral)

Signal:(43.445) Neutral

SK Chemicals Co.,Ltd Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

SK Chemicals Co.,Ltd Correlation - Currency/Commodity

-0.07
( neutral )

0.19
( neutral )

-0.15
( neutral )

-0.06
( neutral )

0.35
( neutral )

0.11
( neutral )

SK Chemicals Co.,Ltd Financials

Annual	2023
Revenue:	KRW1 748.78B
Gross Profit:	KRW460.54B (26.33 %)
EPS:	KRW2 077.30

Q4	2023
Revenue:	KRW431.55B
Gross Profit:	KRW96.68B (22.40 %)
EPS:	KRW-628.39

Q3	2023
Revenue:	KRW581.44B
Gross Profit:	KRW185.20B (31.85 %)
EPS:	KRW2 442.19

Q2	2023
Revenue:	KRW371.34B
Gross Profit:	KRW89.72B (24.16 %)
EPS:	KRW-553.77

Financial Reports:

No articles found.

SK Chemicals Co.,Ltd

SK Chemicals Co., Ltd. provides chemicals and life sciences products and solutions in South Korea and internationally. The company develops copolysters, coating and adhesive materials, engineering plastics, prepergs, bio materials, and 3D printing materials, as well as specialty chemicals, pharmaceutical products, and vaccines. It has a collaborate agreement with Standigm, Inc. to develop an AI-driven drug candidate for non-alcoholic steatohepatitis. The company was founded in 1969 and is headquartered in Seongnam, South Korea.